Citations

Clear

258 citation(s) found for "Ge, Tian".

Follistatin drives neuropathic pain in mice through IGF1R signaling in nociceptive neurons
Jiang, Bao‐Chun , Ling, Yuejuan , Xu, Meng-Lin , Gu, Jun , Sha, Wei‐Lin, Tian, Tian , Bai, Xue‐Hui , Li, Nan , Jiang, Changyu , Ma, Ling-Jie , Zhang, Zhijun , Qin, Yibin , Zhu, Meixuan, Yuan, Hong-Jie, Wu, Long‐Jun , Ling, Yue-Juan , Wu, Xiao-Bo , Bai, Xue-Hui , Jiang, Chang-Yu , Chen, Ouyang , Ma, Ling-Jie , Zhang, Zhi-Jun , Wu, Long-Jun , Ji, Ru-Rong , Gao, Yong-Jing , Xu, Meng-Lin , Li, Nan

Mayo Clinic

Science Translational Medicine | October 16, 2024 | Volume: 16 | Issue: 769 | Pages: No page available

10.1126/scitranslmed.adi1564 | PMID 39413164 Get It

Neuropathic pain is a debilitating chronic condition that lacks effective treatment. The role of cytokine- and chemokine-mediated neuroinflammation in its pathogenesis has been well documented. Follistatin (FST) is a secreted protein known to antagonize the biological activity of cytokines in the transforming growth factor–β (TGF-β) superfamily. The involvement of FST in neuropathic pain and the underlying mechanism remain largely unknown. Here, we report that FST was up-regulated in A-fiber sensory neurons after spinal nerve ligation (SNL) in mice. Inhibition or deletion of FST alleviated neuropathic pain and reduced the nociceptive neuron hyperexcitability induced by SNL. Conversely, intrathecal or intraplantar injection of recombinant FST, or overexpression of FST in the dorsal root ganglion (DRG) neurons, induced pain hypersensitivity. Furthermore, exogenous FST increased neuronal excitability in nociceptive neurons. The biolayer interferometry (BLI) assay and coimmunoprecipitation (co-IP) demonstrated direct binding of FST to the insulin-like growth factor–1 receptor (IGF1R), and IGF1R inhibition reduced FST-induced activation of extracellular signal–regulated kinase (ERK) and protein kinase B (AKT), as well as neuronal hyperexcitability. Further co-IP analysis revealed that the N-terminal domain of FST exhibits the highest affinity for IGF1R, and blocking this interaction with a peptide derived from FST attenuated Nav1.7-mediated neuronal hyperexcitability and neuropathic pain after SNL. In addition, FST enhanced neuronal excitability in human DRG neurons through IGF1R. Collectively, our findings suggest that FST, released from A-fiber neurons, enhances Nav1.7-mediated hyperexcitability of nociceptive neurons by binding to IGF1R, making it a potential target for neuropathic pain treatment.
Germline mutations in a G protein identify signaling cross-talk in T cells
Ham, Hyoungjun , Jing, Huie , Lamborn, Ian T. , Kober, M. , Anderson, David E. , Druey, Kirk M. , Mandl, Judith N. , Isidor, Bertrand , Freeman, Alexandra F. , Ganesan, Sundar , Karsak, Meliha , Mustillo, Peter , Teo, Juliana , Zolkipli‐Cunningham, Zarazuela , Lecoquierre, François , Schmid, Jana Pachlopnik , Kuhns, Douglas B. , Xu, Xuehua , Al–Herz, Waleed , Terhal, Paulien A., Muurinen, Mari , Barlogis, Vincent , Danielson, Jeffrey J. , Stewart, Helen , Rading, Sebastian, Keren, Boris , Pfundt, Rolph , Potocki, Lorraine , Olivier, Kenneth N., Faivre, Laurence , Wong, Melanie , Puel, Anne , Chou, Janet , Tusseau, Maud, Moutsopoulos, Niki M. , Matthews, Helen, Simons, Cas , Fink, Danielle , Kong, Heidi H. , Kabát, Juraj , Kim, Woo Sung , Bierhals, Tatjana , Meguro, Kazuyuki , Gu, Jingwen , Stoddard, Jennifer , Banos-Pinero, Benito, Slack, Maria A., Trivellin, Giampaolo , Mazel, Benoît , Li, Samuel T. , Watts, Val J. , Rodriguez-Quevedo, Maria F. , Bruel, Ange‐Line , Lehalle, Daphné , Torres, Daniel , Sullivan, Kathleen E. , Duffourd, Yannis, Similuk, Morgan , Blanc, Pierre , Jin, Tian, Geha, Raif S., Casanova, Jean‐Laurent , Mäkitie, Outi , Edery, Patrick , Germain, Ronald N. , Billadeau, Daniel D. , Zhang, Yu , Lenardo, Michael J. , Kober, Megan M , Koval, Alexey , Anderson, D Eric , Druey, Kirk M , Mandl, Judith N , Isidor, Bertrand , Ferreira, Carlos R , Freeman, Alexandra F , Karsak, Meliha , Mustillo, Peter J , Teo, Juliana , Chatron, Nicolas , Lecoquierre, Francois , Oler, Andrew J , Schmid, Jana Pachlopnik , Kuhns, Douglas B , Xu, Xuehua , Hauck, Fabian , Al-Herz, Waleed , Wagner, Matias , Terhal, Paulien A , Muurinen, Mari , Barlogis, Vincent , Loid, Petra , Keren, Boris , Pfundt, Rolph , Zarember, Kol A , Vill, Katharina , Olivier, Kenneth N , Lesca, Gaetan , Faivre, Laurence , Puel, Anne , Chou, Janet , Moutsopoulos, Niki M , Simons, Cas , Soldatos, Ariane , Masle-Farquhar, Etienne , Pittaluga, Stefania , Brink, Robert , Kong, Heidi H , Kabat, Juraj , Bierhals, Tatjana , Hsu, Amy P. , Gu, Jingwen , Trivellin, Giampaolo , Mazel, Benoît , Soomann, Maarja , Li, Samuel , Watts, Val J , Stratakis, Constantine A , Rodriguez-Quevedo, Maria F , Bruel, Ange-Line , Lipsanen-Nyman, Marita , Saultier, Paul , Lehalle, Daphne , Torres, Daniel , Barbarot, Sébastien , Neu, Axel , Similuk, Morgan N , McWalter, Kirsty , Blanc, Pierre , Bézieau, Stéphane , Geha, Raif S , Casanova, Jean Laurent , Makitie, Outi M , Edery, Patrick , Christodoulou, John , Germain, Ronald N , Goodnow, Christopher C , Sakmar, Thomas P , Billadeau, Daniel D , Kury, Sebastien , Katanaev, Vladimir L , Zhang, Yu , Lenardo, Michael J , Su, Helen C , Berchiche, Yamina A. , Wagner, Matias , Cruz, Phillip , Lesca, Gaëtan , Tusseau, Maud , Taft, Ryan J. , Pittaluga, Stefania , Baños-Piñero, Benito, Stratakis, Constantine A. , Jain, Rashmi, Bezieau, Stéphane , Jin, Tian , Kubisch, Christian , Küry, Sébastien , Su, Helen C.

Mayo Clinic

Science | September 19, 2024 | Volume: 385 | Issue: 6715 | Pages: No page available

10.1126/science.add8947 | PMID 39298586 Get It

Humans with monogenic inborn errors responsible for extreme disease phenotypes can reveal essential physiological pathways. We investigated germline mutations in GNAI2 , which encodes G αi2 , a key component in heterotrimeric G protein signal transduction usually thought to regulate adenylyl cyclase–mediated cyclic adenosine monophosphate (cAMP) production. Patients with activating G αi2 mutations had clinical presentations that included impaired immunity. Mutant G αi2 impaired cell migration and augmented responses to T cell receptor (TCR) stimulation. We found that mutant G αi2 influenced TCR signaling by sequestering the guanosine triphosphatase (GTPase)–activating protein RASA2, thereby promoting RAS activation and increasing downstream extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT S6 signaling to drive cellular growth and proliferation.
Blocking IL‐23 Signaling Mitigates Cigarette Smoke‐Induced Murine Emphysema
Tian, Xue, Zhang, Chujie , Vassallo, Robert , Vassallo, Robert , Tian, Xue, Wang, Shaohua , Prakash, Y. S.

Mayo Clinic

Environmental Toxicology | September 2, 2024 | Volume: 39 | Issue: 12 | Pages: 5334-5346

10.1002/tox.24405 | PMID 39221838 Get It

ABSTRACTInflammatory cell infiltration is a characteristic feature of COPD and correlates directly with the severity of the disease. Interleukin‐23 (IL‐23) is a pro‐inflammatory cytokine that regulates Th‐17 inflammation, which mediates many pathophysiological events in COPD. The primary goal of this study was to determine the role of IL‐23 as a mediator of key pathologic processes in cigarette smoke‐induced COPD. In this study, we report an increase in IL23 gene expression in the lung biopsies of COPD patients compared to controls and identified a positive correlation between IL23 gene expression and disease severity. In a cigarette smoke‐induced murine emphysema model, the suppression of IL‐23 with a monoclonal blocking antibody reduced the severity of cigarette smoke‐induced murine emphysema. Mechanistically, the suppression of IL‐23 was associated with a reduction in immune cell infiltration, oxidative stress injury, and apoptosis, suggesting a role for IL‐23 as an essential immune mediator of the inflammatory processes in the pathogenesis of CS‐induced emphysema.
Genome-wide polygenic risk scores predict risk of glioma and molecular subtypes
Nakase, Taishi , Guerra, Geno , Ostrom, Quinn T. , Ge, Tian , Melin, Beatrice , Wrensch, Margaret , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , (GICC), Glioma International Case-Control Study, Bondy, Melissa L. , Kachuri, Linda , Guerra, Geno A , Kachuri, Linda , Ge, Tian , Ostrom, Quinn T , Wiencke, John K. , (GICC), Glioma International Case-Control Study, Francis, Stephen

Mayo Clinic

Neuro-Oncology | June 23, 2024 | Volume: 26 | Issue: 10 | Pages: 1933-1944

10.1093/neuonc/noae112 | PMID 38916140 Get It

Abstract Background Polygenic risk scores (PRS) aggregate the contribution of many risk variants to provide a personalized genetic susceptibility profile. Since sample sizes of glioma genome-wide association studies (GWAS) remain modest, there is a need to efficiently capture genetic risk using available data. Methods We applied a method based on continuous shrinkage priors (PRS-CS) to model the joint effects of over 1 million common variants on disease risk and compared this to an approach (PRS-CT) that only selects a limited set of independent variants that reach genome-wide significance (P < 5 × 10–8). PRS models were trained using GWAS stratified by histological (10 346 cases and 14 687 controls) and molecular subtype (2632 cases and 2445 controls), and validated in 2 independent cohorts. Results PRS-CS was generally more predictive than PRS-CT with a median increase in explained variance (R2) of 24% (interquartile range = 11–30%) across glioma subtypes. Improvements were pronounced for glioblastoma (GBM), with PRS-CS yielding larger odds ratios (OR) per standard deviation (SD) (OR = 1.93, P = 2.0 × 10–54 vs. OR = 1.83, P = 9.4 × 10–50) and higher explained variance (R2 = 2.82% vs. R2 = 2.56%). Individuals in the 80th percentile of the PRS-CS distribution had a significantly higher risk of GBM (0.107%) at age 60 compared to those with average PRS (0.046%, P = 2.4 × 10–12). Lifetime absolute risk reached 1.18% for glioma and 0.76% for IDH wildtype tumors for individuals in the 95th PRS percentile. PRS-CS augmented the classification of IDH mutation status in cases when added to demographic factors (AUC = 0.839 vs. AUC = 0.895, PΔAUC = 6.8 × 10–9). Conclusions Genome-wide PRS has the potential to enhance the detection of high-risk individuals and help distinguish between prognostic glioma subtypes.
Tumor microenvironment characteristics association with clinical outcome in patients with resected intestinal-type gastric cancer
Tian, Chunfang , Jing, Haiyan , Wang, Jinshen , Gao, Binbin, Sun, Xiaogang , Song, Wei , Sha, Dan , Tian, Chun-Fang , Yao, Zhi-Gang , Saberzadeh-Ardestani, Bahar , Sha, Dan , Sinicrope, Frank A. , Li, Leping

Mayo Clinic

The Oncologist | June 22, 2024 | Volume: 29 | Issue: 10 | Pages: e1280-e1290

10.1093/oncolo/oyae124 | PMID 38907674 Get It

Abstract Background Tumor microenvironment (TME) characteristics including tumor stroma ratio (TSR), tumor budding (TB), and tumor-infiltrating lymphocytes (TILs) were examined in resected gastric cancer. These TME features have been shown to indicate metastatic potential in colon cancer, and intestinal-type gastric cancer (IGC) has pathological similarities with that malignancy. Methods TSR, TB, and TILs were quantified in routine histological sections from 493 patients with IGC who underwent radical resection at 2 university hospitals in China from 2010 to 2016. TME variables were dichotomized as follows: TSR (50%), TILs (median), TB per international guidelines (4 buds/0.785mm2), and platelet-lymphocyte ratio (PLR) per survival ROC. Association of TME features with patient clinicopathological characteristics, time-to-recurrence (TTR), and cancer-specific-survival (CSS) were examined using univariate and multivariate analysis, including a relative contribution analysis by Cox regression. Results Patients whose tumors showed high TSR or high TB or low TILs were each significantly associated with increased T and N stage, higher histological grade, and poorer TTR and CSS at 5 years. Only TSR and N stage were independently associated with TTR and CSS after adjustment for covariates. PLR was only independently associated with TTR after adjustment for covariates. Among the variables examined, only TSR was significantly associated with both TTR (HR 1.72, 95% CI, 1.14-2.60, P = .01) and CSS (HR 1.62, 95% CI, 1.05-2.51, P = .03) multivariately. Relative contribution to TTR revealed that the top 3 contributors were N stage (45.1%), TSR (22.5%), and PLR (12.9%), while the top 3 contributors to CSS were N stage (59.9%), TSR (14.7%), and PLR (10.9%). Conclusions Among the examined TME features, TSR was the most robust for prognostication and was significantly associated with both TTR and CSS. Furthermore, the relative contribution of TSR to patient TTR and CSS was second only to nodal status.
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome
Ni, Mingke , Saenen, Johan , Hoeksema, Wiert F. , Antiperovitch, Pavel , Arnaud, Marine , Tian, Shanshan, Sun, Bo , Estillore, John Paul , Wang, Ruiwu , Khan, Habib , Roston, Thomas M. , Mazzanti, Andrea , Giudicessi, John, Siontis, Konstantinos C. , Alak, Aiman, Acosta, J. Gabriel , Menon, Syamkumar M. Divakara, Tan, Nigel S. , Vivekanantham, Hari , Pandya, Tanvi, Cunningham, Jennifer , Gula, Lorne J. , Wong, Jorge , Amit, Guy , Scheinman, Melvin M. , Ackerman, Michael J. , Priori, Silvia G. , Sacher, Frédéric , Nof, Eyal , Glikson, Michael , Wilde, Arthur A.M. , Jensen, Henrik Kjærulf , Chen, S.R. Wayne , Roberts, Jason D. , Jensen, Henrik Kjærulf , Mazzanti, Andrea , Priori, Silvia , Dadon, Ziv , Ormerod, Julian O.M. , Tadros, Rafik , Christiansen, Morten Krogh , Steinberg, Christian , Giudicessi, John R. , Werf, Christian van der , Nazer, Babak , Krahn, Andrew D. , Gollob, Michael H. , Healey, Jeff S. , Glikson, Michael , Watkins, Hugh , Postema, Pieter G. , Belhassen, Bernard

Mayo Clinic

JAMA | June 20, 2024 | Volume: 332 | Issue: 3 | Pages: 204

10.1001/jama.2024.8599 | PMID 38900490 Get It

Importance Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest. Objective To explore the cardiac repolarization response on an electrocardiogram after brief tachycardia and a pause as a clinical diagnostic test for CRDS. Design, Setting, and Participants An international, multicenter, case-control study including individual cases of CRDS, 3 patient control groups (individuals with suspected supraventricular tachycardia; survivors of unexplained cardiac arrest [UCA]; and individuals with genotype-positive catecholaminergic polymorphic ventricular tachycardia [CPVT]), and genetic mouse models (CRDS, wild type, and CPVT were used to define the cellular mechanism) conducted at 10 centers in 7 countries. Patient tracings were recorded between June 2005 and December 2023, and the analyses were performed from April 2023 to December 2023. Intervention Brief tachycardia and a subsequent pause (either spontaneous or mediated through cardiac pacing). Main Outcomes and Measures Change in QT interval and change in T-wave amplitude (defined as the difference between their absolute values on the postpause sinus beat and the last beat prior to tachycardia). Results Among 10 case patients with CRDS, 45 control patients with suspected supraventricular tachycardia, 10 control patients who experienced UCA, and 3 control patients with genotype-positive CPVT, the median change in T-wave amplitude on the postpause sinus beat (after brief ventricular tachycardia at ≥150 beats/min) was higher in patients with CRDS ( P < .001). The smallest change in T-wave amplitude was 0.250 mV for a CRDS case patient compared with the largest change in T-wave amplitude of 0.160 mV for a control patient, indicating 100% discrimination. Although the median change in QT interval was longer in CRDS cases ( P = .002), an overlap between the cases and controls was present. The genetic mouse models recapitulated the findings observed in humans and suggested the repolarization response was secondary to a pathologically large systolic release of calcium from the sarcoplasmic reticulum. Conclusions and Relevance There is a unique repolarization response on an electrocardiogram after provocation with brief tachycardia and a subsequent pause in CRDS cases and mouse models, which is absent from the controls. If these findings are confirmed in larger studies, this easy to perform maneuver may serve as an effective clinical diagnostic test for CRDS and become an important part of the evaluation of cardiac arrest.
Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer
Drew, David A. , Kim, Andre E. , Lin, Yi , Morrison, John L. , Lewinger, Juan Pablo , Fu, Yubo, Zemlianskaia, Natalia , Díez‐Obrero, Virginia , Baurley, James W. , Wu, Anna H. , Prentice, Ross L. , Harlid, Sophia , Barry, Elizabeth L. , Berndt, Sonja I. , Bouras, Emmanouil , Burnett‐Hartman, Andrea N. , Casey, Graham , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Newton, Christina C. , Obón‐Santacana, Mireia , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Peters, Ulrike , Gauderman, W. James , Morrison, John L , Lewinger, Juan Pablo , Wang, Jun , Zemlianskaia, Natalia , Bien, Stephanie A , Dimou, Niki , Buchanan, Daniel D , Potter, John D , Prentice, Ross L , Harlid, Sophia , Arndt, Volker , Bouras, Emmanouil , Carreras-Torres, Robert , Casey, Graham , Devall, Matthew A M , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kundaje, Anshul , Li, Li , Lynch, Brigid M , Nassir, Rami , Newton, Christina C , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Pardamean, Bens , Pellatt, Andrew J , Peoples, Anita R , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Su, Yu-Ru , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , Um, Caroline Y , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Hsu, Li , Moreno, Victor , Peters, Ulrike , Chan, Andrew T , Gauderman, W James , Drew, David A , Obón-Santacana, Mireia , Papadimitriou, Nikos , Diez-Obrero, Virginia , Qu, Conghui , Kawaguchi, Eric , Bien, Stephanie A. , Dimou, Niki , Albanes, Demetrius , Buchanan, Daniel D. , Potter, John D. , Arndt, Volker , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T. , Carreras‐Torres, Robert , Conti, David V. , Gunter, Marc J. , Hidaka, Akihisa , Hoffmeister, Michael , Jenkins, Mark A. , Marchand, Loı̈c Le , Murphy, Neil , Nassir, Rami , Newcomb, Polly A. , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Stern, Mariana Carla , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Um, Caroline Y. , White, Emily E. , Moreno, Vı́ctor , Chan, Andrew T.

Mayo Clinic

Science Advances | May 29, 2024 | Volume: 10 | Issue: 22 | Pages: No page available

10.1126/sciadv.adk3121 | PMID 38809988 Get It

Regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on colorectal cancer (CRC) risk. We leveraged pooled data from 52 clinical trial, cohort, and case-control studies that included 30,806 CRC cases and 41,861 controls of European ancestry to conduct a genome-wide interaction scan between regular aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and imputed genetic variants. After adjusting for multiple comparisons, we identified statistically significant interactions between regular aspirin/NSAID use and variants in 6q24.1 (top hit rs72833769 ), which has evidence of influencing expression of TBC1D7 (a subunit of the TSC1-TSC2 complex, a key regulator of MTOR activity), and variants in 5p13.1 (top hit rs350047 ), which is associated with expression of PTGER4 (codes a cell surface receptor directly involved in the mode of action of aspirin). Genetic variants with functional impact may modulate the chemopreventive effect of regular aspirin use, and our study identifies putative previously unidentified targets for additional mechanistic interrogation.
Global modified‐Delphi consensus on comorbidities and prognosis of SCN8A‐related epilepsy and/or neurodevelopmental disorders
Conecker, Gabrielle , Xia, Maya , Hecker, JayEtta , Achkar, Christelle Moufawad El , Cukiert, Cristine Mella , Devries, Seth , Donner, Elizabeth , Fitzgerald, Mark P. , Hammer, Michael F. , Hegde, Anaita , Hu, Chunhui , Luo, Tian , Kooistra, T., Waldrop, Kayla, Youngquist, J. Tyler, Zhang, Dennis, Perry, Μ. Scott , Fitzgerald, Mark , Gardella, Elena , Hammer, Michael , Hu, Chunhui , Kato, Mitsuhiro , Schreiber, John R. , Oudin, Madeleine , Wirrell, Elaine C , Perry, Michael Scott , Gardella, Elena , Wang, Yi , Kooistra, Tammy, Waldrop, Kayla, Youngquist, J. Tyler, Wirrell, Elaine

Mayo Clinic

Epilepsia | May 28, 2024 | Volume: 65 | Issue: 8 | Pages: 2308-2321

10.1111/epi.17991 | PMID 38802989 Get It

AbstractObjectivesWe aimed to develop consensus on comorbidities (frequency, severity, and prognosis) and overall outcomes in epilepsy, development, and cognition for the five phenotypes of SCN8A‐related disorders.MethodsA core panel consisting of 13 clinicians, 1 researcher, and 6 caregivers was formed and split into three workgroups. One group focused on comorbidities and prognosis. All groups performed a literature review and developed questions for use in a modified‐Delphi process. Twenty‐eight clinicians, one researcher, and 13 caregivers from 16 countries participated in three rounds of the modified‐Delphi process. Consensus was defined as follows: strong consensus ≥80% fully agree; moderate consensus ≥80% fully or partially agree, <10% disagree; and modest consensus 67%–79% fully or partially agree, <10% disagree.ResultsConsensus was reached on the presence of 14 comorbidities in patients with Severe Developmental and Epileptic Encephalopathy (Severe DEE) spanning non‐seizure neurological disorders and other organ systems; impacts were mostly severe and unlikely to improve or resolve. Across Mild/Moderate Developmental and Epileptic Encephalopathy (Mild/Moderate DEE), Neurodevelopmental Delay with Generalized Epilepsy (NDDwGE), and NDD without Epilepsy (NDDwoE) phenotypes, cognitive and sleep‐related comorbidities as well as fine and gross motor delays may be present but are less severe and more likely to improve compared to Severe DEE. There was no consensus on comorbidities in the SeL(F)IE phenotype but strong conesensus that seizures would largely resolve. Seizure freedom is rare in patients with Severe DEE but may occur in some with Mild/Moderate DEE and NDDwGE.SignificanceSignificant comorbidities are present in most phenotypes of SCN8A‐related disorders but are most severe and pervasive in the Severe DEE phenotype. We hope that this work will improve recognition, early intervention, and long‐term management for patients with these comorbidities and provide the basis for future evidence‐based studies on optimal treatments of SCN8A‐related disorders. Identifying the prognosis of patients with SCN8A‐related disorders will also improve care and quality‐of‐life for patients and their caregivers.
Global modified Delphi consensus on diagnosis, phenotypes, and treatment of SCN8A‐related epilepsy and/or neurodevelopmental disorders
Conecker, Gabrielle , Xia, Maya , Hecker, JayEtta , Achkar, Christelle Moufawad El , Cukiert, Cristine Mella , Devries, Seth , Donner, Elizabeth , Fitzgerald, Mark P. , Gardella, Elena , Hammer, Michael F. , Hegde, Anaita , Hu, Chunhui , Luo, Tian , Kooistra, T., Waldrop, Kayla, Youngquist, J. Tyler, Zhang, Dennis, Perry, Μ. Scott , Hammer, Michael , Kato, Mitsuhiro , Schreiber, John R. , Oudin, Madeleine , Wirrell, Elaine C , Perry, Michael Scott , Fitzgerald, Mark , Gardella, Elena , Wang, Yi , Kooistra, Tammy, Wirrell, Elaine

Mayo Clinic

Epilepsia | May 28, 2024 | Volume: 65 | Issue: 8 | Pages: 2322-2338

10.1111/epi.17992 | PMID 38802994 Get It

AbstractObjectiveWe aimed to develop consensus for diagnosis/management of SCN8A‐related disorders. Utilizing a modified Delphi process, a global cohort of experienced clinicians and caregivers provided input on diagnosis, phenotypes, treatment, and management of SCN8A‐related disorders.MethodsA Core Panel (13 clinicians, one researcher, six caregivers), divided into three subgroups (diagnosis/phenotypes, treatment, comorbidities/prognosis), performed a literature review and developed questions for the modified Delphi process. Twenty‐eight expert clinicians, one researcher, and 13 caregivers from 16 countries participated in the subsequent three survey rounds. We defined consensus as follows: strong consensus, ≥80% fully agree; moderate consensus, ≥80% fully/partially agree, <10% disagree; and modest consensus, 67%–79% fully/partially agree, <10% disagree.ResultsEarly diagnosis is important for long‐term clinical outcomes in SCN8A‐related disorders. There are five phenotypes: three with early seizure onset (severe developmental and epileptic encephalopathy [DEE], mild/moderate DEE, self‐limited (familial) infantile epilepsy [SeL(F)IE]) and two with later/no seizure onset (neurodevelopmental delay with generalized epilepsy [NDDwGE], NDD without epilepsy [NDDwoE]). Caregivers represented six patients with severe DEE, five mild/moderate DEE, one NDDwGE, and one NDDwoE. Phenotypes vary by age at seizures/developmental delay onset, seizure type, electroencephalographic/magnetic resonance imaging findings, and first‐line treatment. Gain of function (GOF) versus loss of function (LOF) is valuable for informing treatment. Sodium channel blockers are optimal first‐line treatment for GOF, severe DEE, mild/moderate DEE, and SeL(F)IE; levetiracetam is relatively contraindicated in GOF patients. First‐line treatment for NDDwGE is valproate, ethosuximide, or lamotrigine; sodium channel blockers are relatively contraindicated in LOF patients.SignificanceThis is the first‐ever global consensus for the diagnosis and treatment of SCN8A‐related disorders. This consensus will reduce knowledge gaps in disease recognition and inform preferred treatment across this heterogeneous disorder. Consensus of this type allows more clinicians to provide evidence‐based care and empowers SCN8A families to advocate for their children.